Vertex Pharmaceuticals (VRTX) Shares Outstanding (Diluted Average) (2009 - 2026)

Vertex Pharmaceuticals has reported Shares Outstanding (Diluted Average) for 18 years, with the latest figure at $256.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) fell 1.23% year-over-year to $256.3 million; the trailing twelve-month figure through Mar 2026 stood at $256.3 million (down 1.23% YoY), and the FY2025 full-year result was $258.0 million, changed 0.04% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $256.3 million, down from $258.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $261.1 million in Q1 2024, with the low at $256.3 million in Q1 2026.
• Average Shares Outstanding (Diluted Average) over 5 years is $259.0 million, with a median of $258.9 million recorded in 2025.
• Year-over-year, Shares Outstanding (Diluted Average) dropped 1.53% in 2022 and gained 0.93% in 2023.
• Tracing VRTX's Shares Outstanding (Diluted Average) over 5 years: stood at $259.1 million in 2022, then rose by 0.54% to $260.5 million in 2023, then dropped by 1.0% to $257.9 million in 2024, then advanced by 0.04% to $258.0 million in 2025, then declined by 0.66% to $256.3 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $256.3 million (Q1 2026), $258.0 million (Q4 2025), and $257.6 million (Q3 2025), per Business Quant data.

Peer Comparison